UnicoCell Biomed Co., Ltd. (6794) AI Stock Analysis

UnicoCell Biomed Co., Ltd.

(TWSE:6794)

Select Model

Rating:45Neutral

Price Target:TWD 63.00▼(-2.78% Downside)

Action:initiatedcoverage

Date:11/09/26

Solid balance sheet capitalization is the main positive factor, but persistent losses, negative cash flow, and bearish technical momentum are the primary drags on the score.

Positive Factors

Low LeverageVery low leverage reduces fixed financial obligations and gives the company greater flexibility while it funds development-stage operations. The improved debt-to-equity position also provides more capacity to absorb ongoing losses without the immediate pressure associated with a heavily debt-funded balance sheet.

Negative Factors

Revenue VolatilityThe sharp reversal after several years of expansion indicates that revenue is not yet reliably scalable or predictable. Continued top-line volatility can make planning and investment more difficult, while weaker sales reduce operating leverage and increase the time required to reach sustainable profitability.

UnicoCell Biomed Co., Ltd. (6794) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 4.12B
Dividend Yield: ―
Average Volume (3M): 42.02K
Price to Earnings (P/E): -34.1
Beta (1Y): 0.24
Revenue Growth: -48.98%
EPS Growth: -2.09%
Country: TW
Employees: 27
Sector: General
Sector Strength: 55
Industry: Biotechnology

UnicoCell Biomed Co., Ltd. Business Overview & Revenue Model

Company Description

UnicoCell Biomed Co., Ltd., a Taiwanese enterprise, specializes in the research, development, and application of stem cell-based pharmaceuticals, advanced cell therapy techniques, and regenerative medical solutions. Their flagship product, ELIXCYTE,...

UnicoCell Biomed Co., Ltd. Financial Statement Overview

Summary

Strong balance sheet with low debt and high equity offers stability and runway, but weak income statement showing persistent losses plus negative cash flows limit the score.

Income Statement

25Negative

Balance Sheet

82Very Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.10M	30.10M	31.88M	24.59M	14.40M	8.18M
Gross Profit	-221.00K	-221.00K	20.57M	17.90M	8.20M	5.83M
EBITDA	-109.73M	-109.73M	-64.03M	-56.28M	-65.63M	-59.45M
Net Income	-114.84M	-114.84M	-93.07M	-84.11M	-91.16M	-86.37M
Balance Sheet
Total Assets	946.01M	946.01M	777.89M	685.93M	414.31M	297.71M
Cash, Cash Equivalents and Short-Term Investments	752.02M	752.02M	553.52M	477.28M	213.89M	141.02M
Total Debt	62.02M	62.02M	68.24M	74.33M	66.59M	21.58M
Total Liabilities	80.58M	80.58M	93.28M	89.49M	80.46M	34.71M
Stockholders Equity	865.43M	865.43M	684.61M	596.44M	333.85M	263.00M
Cash Flow
Free Cash Flow	-75.97M	-96.81M	-67.22M	-81.53M	-78.21M	-85.70M
Operating Cash Flow	-74.18M	-91.31M	-61.52M	-65.55M	-63.60M	-61.71M
Investing Cash Flow	-300.43M	-173.49M	-122.35M	-307.20M	-164.99M	-23.80M
Financing Cash Flow	176.53M	296.07M	173.54M	339.01M	151.38M	-5.66M

UnicoCell Biomed Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6794 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1760	64Neutral	TWD 4.23B	24.71	―	4.19%	1.43%	-5.24%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6794	45Neutral	TWD 4.10B	-34.13	―	―	-48.98%	-2.09%
TW:3176	42Neutral	TWD 4.62B	-16.65	―	―	1.11%	-94.39%
TW:4726	35Underperform	TWD 4.76B	-12.16	―	―	52.81%	38.53%

* General Sector Average

Performance Comparison

TW:6794 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6794	UnicoCell Biomed Co., Ltd.	64.80	-5.70	-8.09%
TW:1760	Panion & BF Biotech Inc.	47.70	-17.70	-27.07%
TW:3176	Medigen Biotechnology Corporation	30.10	0.15	0.50%
TW:4726	Mycenax Biotech Inc.	22.40	-10.85	-32.63%
TW:6610	TWi Biotechnology, Inc	17.50	-18.80	-51.79%
TW:7920	Tripartite Therapeutics, Inc.	6.85	-0.23	-3.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

UnicoCell Biomed Co., Ltd. AI Stock Analysis